TissGeneSummary for CPA5 |
Gene summary |
Basic gene information | Gene symbol | CPA5 |
Gene name | carboxypeptidase A5 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 7q32 | |
Type of gene | protein-coding | |
RefGenes | NM_001127441.1, NM_001127442.1,NM_080385.4, | |
Description | - | |
Modification date | 20141207 | |
dbXrefs | MIM : 609561 | |
HGNC : HGNC | ||
Ensembl : ENSG00000158525 | ||
HPRD : 07097 | ||
Vega : OTTHUMG00000157824 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_CPA5 | |
BioGPS: 93979 | ||
Pathway | NCI Pathway Interaction Database: CPA5 | |
KEGG: CPA5 | ||
REACTOME: CPA5 | ||
Pathway Commons: CPA5 | ||
Context | iHOP: CPA5 | |
ligand binding site mutation search in PubMed: CPA5 | ||
UCL Cancer Institute: CPA5 | ||
Assigned class in TissGDB* | B | |
Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of CPA5 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for CPA5 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for CPA5 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for CPA5 |
TissGeneSNV for CPA5 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.E338D | COAD | 2 |
p.D348N | UCEC | 1 |
p.S369N | SKCM | 1 |
p.G183D | SKCM | 1 |
p.P435L | LUAD | 1 |
p.G33D | SKCM | 1 |
p.G182R | UCEC | 1 |
p.M358T | COAD | 1 |
p.I380L | LUAD | 1 |
p.V176L | COAD | 1 |
p.L374R | STAD | 1 |
p.G33D | STAD | 1 |
p.P332S | SKCM | 1 |
p.A385G | HNSC | 1 |
p.P79S | COAD | 1 |
p.M376T | BLCA | 1 |
p.S285N | BLCA | 1 |
p.E300G | SKCM | 1 |
p.I195L | UCEC | 1 |
p.A417T | UCEC | 1 |
p.E97* | LUAD | 1 |
p.E88G | PRAD | 1 |
p.P435S | LGG | 1 |
p.Q65* | SKCM | 1 |
p.S370Y | LUAD | 1 |
p.K51N | KIRP | 1 |
p.Y358C | BLCA | 1 |
p.S168N | PAAD | 1 |
p.G100* | SARC | 1 |
p.P240L | HNSC | 1 |
p.A188S | PAAD | 1 |
p.L336S | COAD | 1 |
p.I234T | BLCA | 1 |
p.Y365X | ESCA | 1 |
p.D348N | STAD | 1 |
p.P85L | SKCM | 1 |
p.G393X | STAD | 1 |
p.K51T | READ | 1 |
p.S14C | LUAD | 1 |
p.T209I | SARC | 1 |
p.M106I | SKCM | 1 |
p.E143D | UCEC | 1 |
p.S385L | SKCM | 1 |
p.D158N | READ | 1 |
p.I232V | LUAD | 1 |
p.Y365H | COAD | 1 |
p.Y358H | STAD | 1 |
p.K63T | COAD | 1 |
p.G277V | THYM | 1 |
p.L43I | UCEC | 1 |
p.V382I | SKCM | 1 |
p.D58N | SKCM | 1 |
p.W421L | STAD | 1 |
p.S385* | HNSC | 1 |
p.W70R | HNSC | 1 |
p.V21G | BRCA | 1 |
p.A410T | STAD | 1 |
p.P435H | CESC | 1 |
p.A94T | UCEC | 1 |
p.L101F | UCEC | 1 |
p.D387V | LUAD | 1 |
p.A353V | LGG | 1 |
p.S395N | KIRC | 1 |
p.Y365* | ESCA | 1 |
p.E60Q | CESC | 1 |
p.M328I | SKCM | 1 |
p.E128Q | COAD | 1 |
p.A305V | LIHC | 1 |
p.H203N | LIHC | 1 |
p.S289* | LUAD | 1 |
p.Q52* | LUAD | 1 |
p.D383N | SKCM | 1 |
Top |
TissGeneCNV for CPA5 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for CPA5 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for CPA5 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for CPA5 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for CPA5 |
TissGeneDrug for CPA5 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for CPA5 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0018772 | Hearing Loss, Partial | 1 | GWASCAT |
umls:C1384666 | hearing impairment | 1 | GWASCAT |